Published in Law and Health Weekly, August 19th, 2006
According to recent research published in the journal Infection and Immunity, "Reactivation tuberculosis (TB) is a serious problem in immunocompromised individuals, especially those with human immunodeficiency virus (HIV) co-infection. The adaptive immune response mediated by CD4+ and CD8+ T cells is known to confer protection against TB. Hence, vaccines against TB are designed to activate these two components of the...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Law and Health Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.